About the Author
Dr. Johannes is an associate professor and director of the James L. Voss Veterinary Teaching Hospital at Colorado State University. His industry experience includes working as the former Medical Director at Aratana Therapeutics, Inc., and coordination of the launch of Palladia, the first FDA-approved veterinary cancer therapeutic, during his time with Pfizer Animal Health (now Zoetis, Inc.). Dr. Johannesās practice experience includes primary care, specialty care, and academic settings. His areas of research interest include oncology therapeutic development, immunotherapeutics, and effective management of oncology treatmentārelated side effects.
Written By This Author

Nutrition
The Evolving Clinical Management of Chronic Inappetence
Newer treatments for chronic inappetence include capromorelin for use in dogs and cats and mirtazapine for use in cats.
Oncology
What You Need to Know About New Cancer Treatments for Dogs
Understanding the landscape of available canine cancer therapeutics allows practitioners to offer patients the full array of treatment options.


